All In Biotech

Drug Trial Radar · NCT05046314

A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

The Efficacy and Safety of TK216 in Subjects With Relapsed or Refractory Ewing's Sarcoma:a Phase II Clinical Trial in China

Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Mar 12, 2024

Primary completion

Feb 5, 2025

Study completion Feb 5, 2025

Sponsor

Sponsor type
Industry
First posted
Sep 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, single-arm, open-label Phase II clinical trial evaluating TK216 in combination with vincristine in the treatment of relapsed or refractory Ewing sarcoma (ES) including Ewing's sarcoma family tumors (ESFTs).

Conditions

  • Sarcoma, Ewing

Interventions

  • TK216+VincristinBiological

    TK216 was continuously administered for 14 days,then rest for 14 days. Vincristin is given before TK216 only in the first day of each cycle, the first cycle of VCR is 0.75mg/m\^2 and 1.5mg/m\^2 from the second cycle,every 28 days is a study cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (IRC)Time frame: Up to 2 years after TK216 introduction

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China

  • Tianjin Medical University Cancer Institude & Hospital

    Tianjin, Tianjin Municipality, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.